Cardiome -- CRME Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cardiome -- CRME

CRME 2.330

-2.1%

May 16 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: former_pgs who wrote (105)	11/29/2006 10:36:37 AM
From: kenhott	of 285

Conversion agents have been approved looking primarily at conversion rates for efficacy. Of course available relapse data would be submitted as part of the NDA package. If the duration is nonsense then it wouldn't pass the efficacy hurdle no matter how high the conversion rate. But given a reasonable expectation of duration, conversion rate is the key. Orals are for prevention so recurrence is the key endpoint.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next